About SciVac Therapeutics
SciVac Therapeutics was founded in 2005 in Rehovot, Israel, as a clinical-stage biotechnology company specializing in vaccines for viral infections. A hepatitis B vaccine mimicking all three viral surface antigens was developed, offering rapid protection and lower dosing compared to alternatives. Approval was granted in Israel and 14 other countries. In 2016, merger with VBI Vaccines occurred, with the Israel unit now operating as a contract development organization.
- Headquarter Rehovot, Israel
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
VBI Vaccines
(Oct 26, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of SciVac Therapeutics
Investors in SciVac Therapeutics
SciVac Therapeutics has secured backing from 1 investor. Prominent investors backing the company include VBI Vaccines.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VBI Vaccines is engaged in developing vaccines and immunotherapeutics.
|
Locked | Locked | Locked |
Investor details for SciVac Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SciVac Therapeutics
Investment portfolio details for SciVac Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SciVac Therapeutics
Detailed financials for SciVac Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scivac Therapeutics Comparisons
Peer comparison for SciVac Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SciVac Therapeutics
Detailed competitors of SciVac Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scivac Therapeutics
Complete news archive for SciVac Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SciVac Therapeutics
SciVac Therapeutics was founded in 2005 and raised its 1st funding round 5 years after it was founded.
SciVac Therapeutics is headquartered in Rehovot, Israel. It is registered at Rehovot, Central District, Israel.
SciVac Therapeutics was founded in 2005 in Rehovot, Israel, as a clinical-stage biotechnology company specializing in vaccines for viral infections. A hepatitis B vaccine mimicking all three viral surface antigens was developed, offering rapid protection and lower dosing compared to alternatives. Approval was granted in Israel and 14 other countries. In 2016, merger with VBI Vaccines occurred, with the Israel unit now operating as a contract development organization.
SciVac Therapeutics has 1 investor. Key investors include VBI Vaccines.